Press "esc" to clear
Go to Advanced Search

Showing results

110 of 2515
150401_LItton_J.jpg
  • Embargo expired:
    15-Aug-2018 5:00 PM EDT

Article ID: 699023

PARP inhibitor improves progression-free survival in patients with advanced breast cancers and BRCA mutations

University of Texas M. D. Anderson Cancer Center

In a randomized, Phase III trial led by researchers at The University of Texas MD Anderson Cancer Center, the PARP inhibitor talazoparib extended progression-free survival (PFS) and improved quality-of-life measures over available chemotherapies for patients with metastatic HER2-negative breast cancer and mutations in the BRCA1/2 genes.

Released:
15-Aug-2018 10:05 AM EDT
EXPERT AVAILABLE
Open in New Tab
Add to Favorites
Comment
Embargo will expire:
16-Aug-2018 9:00 AM EDT
Released to reporters:
15-Aug-2018 1:05 PM EDT

EMBARGOED

A reporter's PressPass is required to access this story until the embargo expires on 16-Aug-2018 9:00 AM EDT

MollUte1.jpg

Article ID: 699001

Removing the Most Common p53 Mutation in Colorectal Cancer Halts Disease Progression

Stony Brook University

By genetically manipulating and removing the most common mutant form of the p53 gene that promotes colorectal cancer in humans, an international team of scientists demonstrated that this therapy reduces tumor growth and tissue invasion.

Released:
14-Aug-2018 5:05 PM EDT
EXPERT AVAILABLE
Open in New Tab
Add to Favorites
Comment
Woodworth-inset.jpg

Article ID: 698972

Study Seeks Path for Drugs to Reach Brain Tumors

University of Maryland, Baltimore

The blood-brain barrier is a specialized network of vascular and brain cells that acts as the brain’s security system, helping to safeguard the brain and regulate the flow of substances into and out of it.

Released:
14-Aug-2018 2:05 PM EDT
EXPERT AVAILABLE
Open in New Tab
Add to Favorites
Comment
Embargo will expire:
17-Aug-2018 11:00 AM EDT
Released to reporters:
14-Aug-2018 2:05 PM EDT

EMBARGOED

A reporter's PressPass is required to access this story until the embargo expires on 17-Aug-2018 11:00 AM EDT

Article ID: 698965

Icahn Institute partners in $6.5 million NIH award to advance precision medicine and bioengineering capabilities

Mount Sinai Health System

The National Institutes of Health (NIH) have awarded $6.5 million to a consortium that includes the Icahn Institute for Genomics and Multiscale Biology at the Icahn School of Medicine at Mount Sinai

Released:
14-Aug-2018 12:05 PM EDT
EXPERT AVAILABLE
Open in New Tab
Add to Favorites
Comment

Article ID: 698940

Alarming” Diabetes Epidemic in Guatemala Tied to Aging, Not Obesity

Perelman School of Medicine at the University of Pennsylvania

The diabetes epidemic in Guatemala is worse than previously thought: more than 25 percent of its indigenous people, who make up 60 percent of the population, suffer from type 2 diabetes or pre-diabetes, suggests a new study published in PLOS One from researchers at the Penn Center for Global Health.

Released:
14-Aug-2018 8:05 AM EDT
EXPERT AVAILABLE
Open in New Tab
Add to Favorites
Comment
  • Embargo expired:
    13-Aug-2018 6:30 PM EDT

Article ID: 698655

Switching Anti-Psychotic Medications Doesn’t Improve Outcomes in First-Episode Schizophrenia Patients

Mount Sinai Health System

Switching anti-psychotic medications does not improve clinical outcomes in patients with first-episode schizophrenia who haven’t responded to treatment, Mount Sinai researchers have shown for the first time.

Released:
7-Aug-2018 12:05 PM EDT
EXPERT AVAILABLE
Open in New Tab
Add to Favorites
Comment

Article ID: 698925

One Antiplatelet Drug After Heart Valve Replacement Works as Well as Two, with Fewer Complications

Loyola University Health System

Treatment guidelines say patients who undergo minimally invasive aortic heart valve replacements should receive two antiplatelet drugs to reduce the risk of dangerous blood clots. A Loyola Medicine study has found that a single antiplatelet drug may work just as well, with lower risks of life-threatening bleeding and other complications.

Released:
13-Aug-2018 6:05 PM EDT
EXPERT AVAILABLE
Open in New Tab
Add to Favorites
Comment
Steven_Qian.jpg

Article ID: 698906

NDSU Research Foundation and OncoThira Announce License Agreement to Develop & Market Compounds Discovered at NDSU for the Treatment of Cancer

North Dakota State University

OncoThira will develop and market compounds discovered by NDSU pharmaceutical sciences researcher Steven Qian that take advantage of high COX-2 expression in cancer to down regulate cancer promoting prostaglandins and elevate production of the recently characterized anti-cancer compound 8-HOA

Released:
13-Aug-2018 2:05 PM EDT
EXPERT AVAILABLE
Open in New Tab
Add to Favorites
Comment

Showing results

110 of 2515





Chat now!